CMV prophylaxis: What is valid in 2002?

Nephrology Dialysis Transplantation

Volumn 17, Issue 4, 2002, Pages 556-559

  Heemann, Uwe ^a   Wenzel, Rene R ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; CREATININE; FOSCARNET SODIUM; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; VALACICLOVIR;

ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST; DIARRHEA; DISEASE MARKER; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; HUMAN; KIDNEY TRANSPLANTATION; LEUKOPENIA; NEPHROTOXICITY; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0036222479     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.4.556     Document Type: Article

References (19)

1. Renal transplantation and related infections
2. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients
3. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor
4. Late-acute renal allograft rejection and symptomless cytomegalovirus infection
5. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients
6. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection
7. Cytomegalovirus infection and graft rejection in renal transplantation
8. Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation
9. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation
10. New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients
11. CMV disease in CMV-mismatched renal transplant recipients with prophylactic low dose valaciclovir
12. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
13. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
14. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy
15. Foscarnet-an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation?
16. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
17. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients
18. Preemptive treatment for the prevention of cytomegalovirus disease: In lung and heart transplant recipients
19. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation